Board of Directors

Stéphane Gagné, M.Sc.

President & Chief Executive Officer – Ovensa Inc.

Co-Founder of Ovensa and three other companies, Mr. Gagné holds 20 years of experience in the pharmaceutical (anticancer drugs and drug delivery), cosmetics and nutritional supplements industries. He was instrumental to the growth of Aeterna-Zentaris, a company that was developing an angiogenesis inhibitor for non-small cell lung cancer. He was also a co-founder of Constab Pharmaceutical, a company developing a drug delivery system using alpha-fetoprotein. Mr. Gagné also contributed to the international expansion of Atrium Biotechnologies and several Canadian private and public companies. He is recognized for his leadership, for building teams, growing sales and for his negotiation skills. He holds 2 bachelor degrees (Economics and Multidisciplinary), has a Master Degree in Business Administration and speaks several languages.

Steven Splinter, Ph.D.


A science entrepreneur with over 18 years of corporate, strategic and operational experience (13 years in Executive or Senior Management roles).  Successfully founded, raised investment rounds and led initial corporate and all technical development for an agri-based bio-innovation company. Experienced in strategic planning, technical assessment and development of process technologies, business leadership, and engineering project management.

Neil Klompas, CPA, CA

EVP Business Operations & CFO – Zymeworks

Mr. Klompas is the Executive Vice President and Chief Financial Officer of Zymeworks Inc. (NYSE: ZYME), a clinical stage biotechnology company based in Vancouver.  Neil brings over 20 years of healthcare and biotechnology experience. Prior to joining Zymeworks in 2007 he worked with KPMG LLP in Canada and the United States, including with KPMG’s Pharmaceutical, Biotechnology and Medical Device M&A Transaction Services practice in Princeton, New Jersey, where he advised on numerous transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice. Mr. Klompas is a Chartered Professional Accountant and is a member of Chartered Professional Accountants of British Columbia. Mr. Klompas also holds a degree in Microbiology & Immunology from the University of British Columbia and currently serves on the board of Liminal BioSciences Inc. (NASDAQ/TSX: LMNL), and on the faculty advisory board for Biotechnology and Chemistry for Camosun College. He formerly served as a Director for the Canadian Gene Cure Foundation, and currently assists the Canadian Cancer Society on initiatives in British Columbia.

Christophe Goffoz

President – Divergent Capital & Lead Investor – Anges Québec

A Chemical / Process Engineer and holder of a Master’s Degree in Marketing from HEC Paris, Christophe spent the first part of his professional life in the pharmaceutical industry in Europe and then in Canada. He explores various therapeutic areas in which he works as much on the marketing side of innovative products as on the commercial development of existing drugs. In January 2016, a new chapter opened for him with the creation of Divergent Capital, a private investment fund dedicated to impact investment.  As the founding president of Divergent Capital, Christophe now supports start-up entrepreneurs by providing them with the financial and mentoring support they need to succeed.

Passionate and dynamic, Christophe shares his experience and creativity in business with his network and the entrepreneurs he coaches. Competitive by nature, he also practices high-level sports both individually (tennis) and collectively (volleyball).

Manon Boisclair

Executive Leader – BioPharma & Life Sciences,
Founder – InnovID B2

Mrs. Boisclair earned an undergraduate degree and MSc in Nursing as well as an executive MBA at McGill, and is pursuing additional executive education at Harvard University. Her interdisciplinary scientific and business training contributes to her deep understanding of complex pharma/biotech and business issues. Mrs. Boisclair has over 20 years of international, executive-level Medical Affairs experience in NASDAQ-listed pharma and biotech companies working in Canada, the US and Europe (Merck, Novartis, Celgene, Intercept). She has extensive experience across therapeutic areas including oncology, liver diseases and cardiology with several blockbusters in pre/post-launch medical-marketing initiatives overseeing scientific communications, digital innovation and operations. Mrs Boisclair is also a founder of InnovID B2, a firm specialized in MedTech business development as well as being a mentor at Centech for start-up companies in life sciences.